ACLX
Price
$72.62
Change
+$0.46 (+0.64%)
Updated
Sep 5 closing price
Capitalization
4.03B
71 days until earnings call
EXEL
Price
$37.88
Change
+$0.50 (+1.34%)
Updated
Sep 5 closing price
Capitalization
10.2B
58 days until earnings call
Interact to see
Advertisement

ACLX vs EXEL

Header iconACLX vs EXEL Comparison
Open Charts ACLX vs EXELBanner chart's image
Arcellx
Price$72.62
Change+$0.46 (+0.64%)
Volume$364.16K
Capitalization4.03B
Exelixis
Price$37.88
Change+$0.50 (+1.34%)
Volume$2.52M
Capitalization10.2B
ACLX vs EXEL Comparison Chart in %
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACLX vs. EXEL commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Buy and EXEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (ACLX: $72.62 vs. EXEL: $37.88)
Brand notoriety: ACLX: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 75% vs. EXEL: 80%
Market capitalization -- ACLX: $4.03B vs. EXEL: $10.2B
ACLX [@Biotechnology] is valued at $4.03B. EXEL’s [@Biotechnology] market capitalization is $10.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileEXEL’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • EXEL’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than ACLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 7 TA indicator(s) are bullish while EXEL’s TA Score has 5 bullish TA indicator(s).

  • ACLX’s TA Score: 7 bullish, 2 bearish.
  • EXEL’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ACLX is a better buy in the short-term than EXEL.

Price Growth

ACLX (@Biotechnology) experienced а +4.65% price change this week, while EXEL (@Biotechnology) price change was +1.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ACLX is expected to report earnings on Nov 17, 2025.

EXEL is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.2B) has a higher market cap than ACLX($4.03B). EXEL YTD gains are higher at: 13.754 vs. ACLX (-5.307). EXEL has higher annual earnings (EBITDA): 782M vs. ACLX (-179.78M). EXEL has more cash in the bank: 791M vs. ACLX (453M). ACLX has less debt than EXEL: ACLX (52.5M) vs EXEL (180M). EXEL has higher revenues than ACLX: EXEL (2.23B) vs ACLX (57M).
ACLXEXELACLX / EXEL
Capitalization4.03B10.2B39%
EBITDA-179.78M782M-23%
Gain YTD-5.30713.754-39%
P/E RatioN/A18.21-
Revenue57M2.23B3%
Total Cash453M791M57%
Total Debt52.5M180M29%
FUNDAMENTALS RATINGS
EXEL: Fundamental Ratings
EXEL
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
PROFIT vs RISK RATING
1..100
35
SMR RATING
1..100
34
PRICE GROWTH RATING
1..100
55
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACLXEXEL
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
73%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
67%
Advances
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
64%
Declines
ODDS (%)
Bearish Trend 14 days ago
78%
Bearish Trend 5 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAVKX15.010.03
+0.20%
MoA Small Cap Value Fund
CZMGX20.27-0.02
-0.10%
Multi-Manager Growth Strategies Inst
PACLX37.06-0.14
-0.38%
T. Rowe Price Capital Appreciation Adv
IAUTX27.97-0.14
-0.50%
Invesco Dividend Income A
BEGIX22.30-0.22
-0.98%
Sterling Capital Equity Income Instl

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with RNA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+0.64%
RNA - ACLX
55%
Loosely correlated
+3.90%
CGON - ACLX
55%
Loosely correlated
+6.88%
ROIV - ACLX
54%
Loosely correlated
+2.78%
XNCR - ACLX
52%
Loosely correlated
+2.15%
CRNX - ACLX
52%
Loosely correlated
+3.97%
More

EXEL and

Correlation & Price change

A.I.dvisor tells us that EXEL and LQDA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and LQDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.34%
LQDA - EXEL
31%
Poorly correlated
+0.03%
JAZZ - EXEL
30%
Poorly correlated
+1.16%
RIGL - EXEL
29%
Poorly correlated
+3.02%
ACLX - EXEL
29%
Poorly correlated
+0.64%
ADCT - EXEL
29%
Poorly correlated
+4.12%
More